G-CSF-induced mobilization of bone marrow stem cells and cardiac repair

Milestones in Drug Therapy

Volumn 43, Issue , 2012, Pages 435-462

  Dawn, Buddhadeb ^a   Sanganalmath, Santosh K ^a   Bolli, Roberto ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CONNEXIN 43; CYCLOPHOSPHAMIDE; FLT3 LIGAND; GAMMA INTERFERON; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; JANUS KINASE 1; JANUS KINASE 2; N(G) NITROARGININE METHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PROTEIN KINASE TYK2; PROTEINASE; RECOMBINANT ERYTHROPOIETIN; SITAGLIPTIN; STAT3 PROTEIN; STAT5 PROTEIN; STEEL FACTOR; STEM CELL FACTOR RECEPTOR; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN C;

ACUTE HEART INFARCTION; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL REGENERATION; CONGESTIVE CARDIOMYOPATHY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; GENE DELIVERY SYSTEM; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; ISCHEMIC CARDIOMYOPATHY; LOW DRUG DOSE; META ANALYSIS (TOPIC); MONOTHERAPY; NEUTROPENIA; NONHUMAN; NONISCHEMIC CARDIOMYOPATHY; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION; TREATMENT DURATION;

EID: 84867002291     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0348-0218-5_24     Document Type: Article

References (117)

1. Arai KI, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T (1990) Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 59:783-836.
2. Pimentel E (1990) Colony-stimulating factors. Ann Clin Lab Sci 20:36-55.
3. Lapidot T, Petit I (2002) Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 30:973-981.
4. Papayannopoulou T (2004) Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood 103:1580-1585.
5. Anderlini P, Donato M, Chan KW et al (1999) Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the MD Anderson Cancer Center experience. Transfusion 39:555-560.
6. Orlic D, Kajstura J, Chimenti S et al (2001) Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 98:10344-10349.
7. Minatoguchi S, Takemura G, Chen XH et al (2004) Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 109:2572-2580.
8. Iwanaga K, Takano H, Ohtsuka M et al (2004) Effects of G-CSF on cardiac remodeling after acute myocardial infarction in swine. Biochem Biophys Res Commun 325:1353-1359.
9. Dawn B, Guo Y, Rezazadeh A et al (2006) Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. Circ Res 98:1098-1105.
10. Harada M, Qin Y, Takano H et al (2005) G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 11:305-311.
11. Kuhlmann MT, Kirchhof P, Klocke R et al (2006) G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis. J Exp Med 203:87-97.
12. Deindl E, Zaruba MM, Brunner S et al (2006) G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J 20:956-958.
13. Abdel-Latif A, Bolli R, Zuba-Surma EK, Tleyjeh IM, Hornung CA, Dawn B (2008) Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Am Heart J 156:216-226.
14. Zohlnhofer D, Dibra A, Koppara T et al (2008) Stem cell mobilization by granulocyte colonystimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. J Am Coll Cardiol 51:1429-1437.
15. Ripa RS, Jorgensen E, Wang Y et al (2006) Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 113:1983-1992.
16. Zohlnhofer D, Ott I, Mehilli J et al (2006) Stem cell mobilization by granulocyte colonystimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 295:1003-1010.
17. Avalos BR (1996) Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 88:761-777.
18. Touw IP, van de Geijn GJ (2007) Granulocyte colony-stimulating factor and its receptor in normal myeloid cell development, leukemia and related blood cell disorders. Front Biosci 12:800-815.
19. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D (1988) Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72:2074-2081.
20. Molineux G, Pojda Z, Hampson IN, Lord BI, Dexter TM (1990) Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood 76:2153-2158.
21. Liu F, Poursine-Laurent J, Link DC (1997) The granulocyte colony-stimulating factor receptor is required for the mobilization of murine hematopoietic progenitors into peripheral blood by cyclophosphamide or interleukin-8 but not flt-3 ligand. Blood 90:2522-2528.
22. Liu F, Poursine-Laurent J, Link DC (2000) Expression of the G-CSF receptor on hematopoietic progenitor cells is not required for their mobilization by G-CSF. Blood 95:3025-3031.
23. Kronenwett R, Martin S, Haas R (2000) The role of cytokines and adhesion molecules for mobilization of peripheral blood stem cells. Stem Cells 18:320-330.
24. Nervi B, Link DC, DiPersio JF (2006) Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 99:690-705.
25. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ (2001) Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 98:1289-1297.
26. Levesque JP, Hendy J, Takamatsu Y, Williams B, Winkler IG, Simmons PJ (2002) Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol 30:440-449.
27. Petit I, Szyper-Kravitz M, Nagler A et al (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3:687-694.
28. Levesque JP, Hendy J, Winkler IG, Takamatsu Y, Simmons PJ (2003) Granulocyte colonystimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells. Exp Hematol 31: 109-117.
29. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ (2003) Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 111:187-196.
30. Levesque JP, Liu F, Simmons PJ et al (2004) Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 104:65-72.
31. Masure S, Proost P, Van Damme J, Opdenakker G (1991) Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur J Biochem 198:391-398.
32. Kjeldsen L, Sengelov H, Lollike K, Nielsen MH, Borregaard N (1994) Isolation and characterization of gelatinase granules from human neutrophils. Blood 83:1640-1649.
33. Pruijt JF, Fibbe WE, Laterveer L et al (1999) Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc Natl Acad Sci USA 96:10863-10868.
34. Pelus LM, Bian H, King AG, Fukuda S (2004) Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood 103:110-119.
35. Kollet O, Dar A, Shivtiel S et al (2006) Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 12:657-664.
36. Christopherson KW, Cooper S, Hangoc G, Broxmeyer HE (2003) CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26/mice. Exp Hematol 31:1126-1134.
37. Vagima Y, Avigdor A, Goichberg P et al (2009) MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization. J Clin Invest 119:492-503.
38. Nagasawa T, Kikutani H, Kishimoto T (1994) Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A 91:2305-2309.
39. Semerad CL, Christopher MJ, Liu F et al (2005) G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 106:3020-3027.
40. Dlubek D, Drabczak-Skrzypek D, Lange A (2006) Low CXCR4 membrane expression on CD34(+) cells characterizes cells mobilized to blood. Bone Marrow Transplant 37:19-23.
41. Kim HK, De La Luz Sierra M, Williams CK, Gulino AV, Tosato G (2006) G-CSF downregulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood 108:812-820.
42. Abdel-Latif A, Bolli R, Tleyjeh IM et al (2007) Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 167:989-997.
43. Dawn B, Abdel-Latif A, Sanganalmath SK, Flaherty MP, Zuba-Surma EK (2009) Cardiac repair with adult bone marrow-derived cells: the clinical evidence. Antioxid Redox Signal 11:1865-1882.
44. Ohtsuka M, Takano H, Zou Y et al (2004) Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J 18:851-853.
45. Takahama H, Minamino T, Hirata A et al (2006) Granulocyte colony-stimulating factor mediates cardioprotection against ischemia/reperfusion injury via phosphatidylinositol-3kinase/Akt pathway in canine hearts. Cardiovasc Drugs Ther 20:159-165.
46. Werneck-de-Castro JP, Costa ESRH, de Oliveira PF et al (2006) G-CSF does not improve systolic function in a rat model of acute myocardial infarction. Basic Res Cardiol 101: 494-501.
47. Hasegawa H, Takano H, Iwanaga K et al (2006) Cardioprotective effects of granulocyte colony-stimulating factor in swine with chronic myocardial ischemia. J Am Coll Cardiol 47:842-849.
48. Li Y, Takemura G, Okada H et al (2006) Treatment with granulocyte colony-stimulating factor ameliorates chronic heart failure. Lab Invest 86:32-44.
49. Louzada RA, Oliveira PF, Cavalcanti-de-Albuquerque JP et al (2010) Granulocyte-colony stimulating factor treatment of chronic myocardial infarction. Cardiovasc Drugs Ther 24:121-130.
50. Miyata S, Takemura G, Kawase Y et al (2006) Autophagic cardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocyte colony-stimulating factor. Am J Pathol 168:386-397.
51. Hou XW, Son J, Wang Y et al (2006) Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther 20:85-91.
52. Menendez P, Caballero MD, Prosper F et al (2002) The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen. Transfusion 42:1159-1172.
53. Costa JJ, Demetri GD, Harrist TJ et al (1996) Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 183:2681-2686.
54. Broudy VC (1997) Stem cell factor and hematopoiesis. Blood 90:1345-1364.
55. Bodine DM, Seidel NE, Gale MS, Nienhuis AW, Orlic D (1994) Efficient retrovirus transduction of mouse pluripotent hematopoietic stem cells mobilized into the peripheral blood by treatment with granulocyte colony-stimulating factor and stem cell factor. Blood 84: 1482-1491.
56. Kawamoto A, Murayama T, Kusano K et al (2004) Synergistic effect of bone marrow mobilization and vascular endothelial growth factor-2 gene therapy in myocardial ischemia. Circulation 110:1398-1405.
57. Norol F, Merlet P, Isnard R et al (2003) Influence of mobilized stem cells on myocardial infarct repair in a nonhuman primate model. Blood 102:4361-4368.
58. Lyman SD (1998) Biologic effects and potential clinical applications of Flt3 ligand. Curr Opin Hematol 5:192-196.
59. Ashihara E, Shimazaki C, Sudo Y et al (1998) FLT-3 ligand mobilizes hematopoietic primitive and committed progenitor cells into blood in mice. Eur J Haematol 60:86-92.
60. Molineux G, McCrea C, Yan XQ, Kerzic P, McNiece I (1997) Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 89:3998-4004.
61. Sudo Y, Shimazaki C, Ashihara E et al (1997) Synergistic effect of FLT-3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice. Blood 89:3186-3191.
62. Neipp M, Zorina T, Domenick MA, Exner BG, Ildstad ST (1998) Effect of FLT3 ligand and granulocyte colony-stimulating factor on expansion and mobilization of facilitating cells and hematopoietic stem cells in mice: kinetics and repopulating potential. Blood 92:3177-3188.
63. Sanganalmath SK, Stein AB, Guo Y et al (2009) The beneficial effects of postinfarct cytokine combination therapy are sustained during long-term follow-up. J Mol Cell Cardiol 47: 528-535.
64. Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 228:1-14.
65. Calvillo L, Latini R, Kajstura J et al (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100:4802-4806.
66. Parsa CJ, Matsumoto A, Kim J et al (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112:999-1007.
67. Cai Z, Semenza GL (2004) Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 109:2050-2053.
68. Moon C, Krawczyk M, Ahn D et al (2003) Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 100:11612-11617.
69. Heeschen C, Aicher A, Lehmann R et al (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102:1340-1346.
70. Prunier F, Pfister O, Hadri L et al (2007) Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 292:H522-H529.
71. Westenbrink BD, Lipsic E, van der Meer P et al (2007) Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 28:2018-2027.
72. Yeghiazarians Y, Khan M, Angeli FS et al (2010) Cytokine combination therapy with longacting erythropoietin and granulocyte colony stimulating factor improves cardiac function but is not superior than monotherapy in a mouse model of acute myocardial infarction. J Card Fail 16:669-678.
73. Angeli FS, Amabile N, Shapiro M et al (2010) Cytokine combination therapy with erythropoietin and granulocyte colony stimulating factor in a porcine model of acute myocardial infarction. Cardiovasc Drugs Ther 24:409-420.
74. Quinn CM, Dawn B (2010) G-CSF and erythropoietin combination therapy for infarct repair: two plus two equals two? Cardiovasc Drugs Ther 24:369-371.
75. Fukuhara S, Tomita S, Nakatani T et al (2004) G-CSF promotes bone marrow cells to migrate into infarcted mice heart, and differentiate into cardiomyocytes. Cell Transplant 13:741-748.
76. Kawada H, Fujita J, Kinjo K et al (2004) Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 104: 3581-3587.
77. Deten A, Volz HC, Clamors S et al (2005) Hematopoietic stem cells do not repair the infarcted mouse heart. Cardiovasc Res 65:52-63.
78. Askari AT, Unzek S, Popovic ZB et al (2003) Effect of stromal-cell-derived factor 1 on stemcell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362:697-703.
79. Adachi Y, Imagawa J, Suzuki Y et al (2004) G-CSF treatment increases side population cell infiltration after myocardial infarction in mice. J Mol Cell Cardiol 36:707-710.
80. Misao Y, Takemura G, Arai M et al (2006) Importance of recruitment of bone marrowderived CXCR4+ cells in post-infarct cardiac repair mediated by G-CSF. Cardiovasc Res 71: 455-465.
81. Ueda K, Takano H, Hasegawa H et al (2006) Granulocyte colony stimulating factor directly inhibits myocardial ischemia-reperfusion injury through Akt-endothelial NO synthase pathway. Arterioscler Thromb Vasc Biol 26:e108-e113.
82. Ohki Y, Heissig B, Sato Y et al (2005) Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. FASEB J 19:2005-2007.
83. Capoccia BJ, Shepherd RM, Link DC (2006) G-CSF and AMD3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanism. Blood 108:2438-2445.
84. Kanellakis P, Slater NJ, Du XJ, Bobik A, Curtis DJ (2006) Granulocyte colony-stimulating factor and stem cell factor improve endogenous repair after myocardial infarction. Cardiovasc Res 70:117-125.
85. Sugano Y, Anzai T, Yoshikawa T et al (2005) Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. Cardiovasc Res 65:446-456.
86. Fujita J, Mori M, Kawada H et al (2007) Administration of granulocyte colony-stimulating factor after myocardial infarction enhances the recruitment of hematopoietic stem cellderived myofibroblasts and contributes to cardiac repair. Stem Cells 25:2750-2759.
87. Hartung T (1998) Anti-inflammatory effects of granulocyte colony-stimulating factor. Curr Opin Hematol 5:221-225.
88. Boneberg EM, Hareng L, Gantner F, Wendel A, Hartung T (2000) Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma. Blood 95:270-276.
89. Kang HJ, Kim HS, Zhang SY et al (2004) Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 363:751-756.
90. Ince H, Petzsch M, Kleine HD et al (2005) Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial. Circulation 112:I73-I80.
91. Ince H, Petzsch M, Kleine HD et al (2005) Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 112:3097-3106.
92. Kuethe F, Figulla HR, Herzau M et al (2005) Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction. Am Heart J 150:115.
93. Valgimigli M, Rigolin GM, Cittanti C et al (2005) Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. Eur Heart J 26:1838-1845.
94. Takano H, Hasegawa H, Kuwabara Y et al (2007) Feasibility and safety of granulocyte colony-stimulating factor treatment in patients with acute myocardial infarction. Int J Cardiol 122:41-47.
95. Leone AM, Galiuto L, Garramone B et al (2007) Usefulness of granulocyte colonystimulating factor in patients with a large anterior wall acute myocardial infarction to prevent left ventricular remodeling (the rigenera study). Am J Cardiol 100:397-403.
96. Ellis SG, Penn MS, Bolwell B et al (2006) Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial. Am Heart J 152:1051.e9-1051.e14.
97. Engelmann MG, Theiss HD, Hennig-Theiss C et al (2008) Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the GCSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J Am Coll Cardiol 48:1712-1721.
98. Engelmann MG, Theiss HD, Theiss C et al (2010) G-CSF in patients suffering from late revascularised ST elevation myocardial infarction: final 1-year-results of the G-CSF-STEMI Trial. Int J Cardiol 144:399-404.
99. Ince H, Valgimigli M, Petzsch M et al (2008) Cardiovascular events and re-stenosis following administration of G-CSF in acute myocardial infarction: systematic review and meta-analysis. Heart 94:610-616.
100. Wang Y, Tagil K, Ripa RS et al (2005) Effect of mobilization of bone marrow stem cells by granulocyte colony stimulating factor on clinical symptoms, left ventricular perfusion and function in patients with severe chronic ischemic heart disease. Int J Cardiol 100:477-483.
101. Hill JM, Bartunek J (2006) The end of granulocyte colony-stimulating factor in acute myocardial infarction? Reaping the benefits beyond cytokine mobilization. Circulation 113:1926-1928.
102. Ripa RS, Wang Y, Jorgensen E, Johnsen HE, Hesse B, Kastrup J (2006) Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocytecolony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J 27:1785-1792.
103. Huttmann A, Duhrsen U, Stypmann J et al (2006) Granulocyte colony-stimulating factorinduced blood stem cell mobilisation in patients with chronic heart failure-feasibility, safety and effects on exercise tolerance and cardiac function. Basic Res Cardiol 101:78-86.
104. Schachinger V, Erbs S, Elsasser A et al (2006) Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355:1210-1221.
105. Achilli F, Malafronte C, Lenatti L et al (2010) Granulocyte colony-stimulating factor attenuates left ventricular remodelling after acute anterior STEMI: results of the singleblind, randomized, placebo-controlled multicentre STem cEll Mobilization in Acute Myocardial Infarction (STEM-AMI) Trial. Eur J Heart Fail 12:1111-1121.
106. Theiss HD, Brenner C, Engelmann MG et al (2010) Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)-rationale, design and first interim analysis. Int J Cardiol 145:282-284.
107. Li Y, Fukuda N, Yokoyama S et al (2006) Effects of G-CSF on cardiac remodeling and arterial hyperplasia in rats. Eur J Pharmacol 549:98-106.
108. Beohar N, Flaherty JD, Davidson CJ et al (2007) Granulocyte-colony stimulating factor administration after myocardial infarction in a porcine ischemia-reperfusion model: functional and pathological effects of dose timing. Catheter Cardiovasc Interv 69:257-266.
109. Ieishi K, Nomura M, Kawano T et al (2007) The effect of G-CSF in a myocardial ischemia reperfusion model rat. J Med Invest 54:177-183.
110. Cheng Z, Ou L, Liu Y et al (2008) Granulocyte colony-stimulating factor exacerbates cardiac fibrosis after myocardial infarction in a rat model of permanent occlusion. Cardiovasc Res 80:425-434.
111. Angeli FS, Smith C, Amabile N et al (2010) Granulocyte colony stimulating factor in myocardial infarction with low ejection fraction. Cytokine 51:278-285.
112. Tomita S, Ishida M, Nakatani T et al (2004) Bone marrow is a source of regenerated cardiomyocytes in doxorubicin-induced cardiomyopathy and granulocyte colony-stimulating factor enhances migration of bone marrow cells and attenuates cardiotoxicity of doxorubicin under electron microscopy. J Heart Lung Transplant 23:577-584.
113. Li L, Takemura G, Li Y et al (2007) Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy. Lab Invest 87:440-455.
114. de Suarez lezo J, Torres A, Herrera I et al (2005) Effects of stem-cell mobilization with recombinant human granulocyte colony stimulating factor in patients with percutaneously revascularized acute anterior myocardial infarction. Rev Esp Cardiol 58:253-261.
115. Leone AM, Rutella S, Bonanno G et al (2006) Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction. Int J Cardiol 111:202-208.
116. Suzuki K, Nagashima K, Arai M et al (2006) Effect of granulocyte colony-stimulating factor treatment at a low dose but for a long duration in patients with coronary heart disease. Circ J 70:430-437.
117. Hill JM, Syed MA, Arai AE et al (2005) Outcomes and risks of granulocyte colonystimulating factor in patients with coronary artery disease. J Am Coll Cardiol 46:1643-1648.